Therefore, in our pursuit of discovering the metabolic effect of metformin on breast cancers at a molecular level, we focused on a single ER-positive breast cancer cell line, MCF-7, and tested the extrapolations of the results reported for the triple-negative breast cancers. Here, ESR1 is linked to triple-negative breast carcinoma.